331 related articles for article (PubMed ID: 17095209)
1. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
Hartmann JT; Mayer F; Schleicher J; Horger M; Huober J; Meisinger I; Pintoffl J; Käfer G; Kanz L; Grünwald V;
Cancer; 2007 Aug; 110(4):861-6. PubMed ID: 17599772
[TBL] [Abstract][Full Text] [Related]
7. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
[TBL] [Abstract][Full Text] [Related]
8. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
9. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Reichardt P; Nielsen OS; Bauer S; Hartmann JT; Schöffski P; Christensen TB; Pink D; Daugaard S; Marreaud S; Van Glabbeke M; Blay JY;
Eur J Cancer; 2007 Apr; 43(6):1017-22. PubMed ID: 17336054
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
12. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
16. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
17. New emerging drugs in soft tissue sarcoma.
Milano A; Apice G; Ferrari E; Fazioli F; de Rosa V; de Luna AS; Iaffaioli RV; Caponigro F
Crit Rev Oncol Hematol; 2006 Jul; 59(1):74-84. PubMed ID: 16533604
[TBL] [Abstract][Full Text] [Related]
18. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Patel SR; Beach J; Papadopoulos N; Burgess MA; Trent J; Jenkins J; Benjamin RS
Cancer; 2003 Jun; 97(11):2848-52. PubMed ID: 12767099
[TBL] [Abstract][Full Text] [Related]
19. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
van Erp N; Gelderblom H; van Glabbeke M; Van Oosterom A; Verweij J; Guchelaar HJ; Debiec-Rychter M; Peng B; Blay JY; Judson I
Clin Cancer Res; 2008 Dec; 14(24):8308-13. PubMed ID: 19088049
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
